博彩导航

姓名： 章彬 职务： 职称： 讲师 政治面貌： 中共党员 最高学历学位： 博士、研究生 专业: 药学 所属院系: 药学院（筹） 研究方向: 药物化学 电话: 信箱: [email protected] 个人主页:

个人简介

目前从事的主要科研工作：小分子药物（或分子探针）的设计合成及抗肿瘤、抗神经退行性疾病研究；天然产物（海洋来源）的结构优化与活性评价。2021年入选宁波市领军和拔尖人才培养工程（第三层次），现任浙江省药学会药物化学与抗生素专委会第二届青委会委员、国家食药同源产业科技创新联盟会员。受邀作为European Journal of Medicinal Chemistry，Expert Opinion On Drug Discovery，Current Medicinal Chemistry，Combinatorial Chemistry & High Throughput Screening等多个期刊审稿人。目前以第一或通讯作者身份发表文章20余篇，授权专利5项。作为本科生指导教师，近三年来获大学生生命科学竞赛（创新创业类）全国一等奖、大学生“挑战杯”浙江省三等奖、大学生生命科学竞赛浙江省三等奖、宁波大学学生科研创新计划（SRIP）重点项目3项。

学习和工作经历

2004-2008   安徽理工大学 制药工程（化学） 工学学士

2008-2011   北京工业大学 生物化学与分子生物学 理学硕士

2011-2015   清华大学 化学 理学博士

2015-2017   沈阳药科大学 药物化学 博士后

2017-至今   博彩平台推荐-博彩导航

近年发表的主要论文

1. Z. Wang, L. Zhao, B. Zhang, J. Feng, Y. Wang, B. Zhang*, H. Jin, L. Ding, N. Wang*, S. He*, Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy, Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, 2206581.

2. H. Yang, Q. Zhang, B. Zhang*, Y. Zhao, N. Wang*, Potential Active Marine Peptides as Anti-Aging Drugs or Drug Candidates, Marine Drugs, 2023, 21, 144.

3. L. Fang, S. He, P. Yin, N. Wang, B. Zhang*, H. Jin*, Design, synthesis, and structure–Activity relationship studies of novel tryptamine derivatives as 5‑HT1B receptor agonists, Journal of Molecular Structure, 2022, 1265, 133320.

4. Z. Liu, A. Jiang, Y. Wang, P. Xu, Q. Zhang, Y. Wang, S. He, N. Wang*, H. Jin*, B. Zhang*, In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors, Bioorganic & Medicinal Chemistry Letters, 2022, 67, 128759.

5. Y. Lu*, Z. Hou, M. Li, N. Wang, J. Wang, F. Ni, Y. Zhao, B. Zhang*, N. Xi*, Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron-donating ability of 1,10-phenanthroline ligands, Dalton Trans, 2022, 51, 16224-16235.

6. T. Wang, Z. Hou, X. Chen, L. Zhao, D. Zhu, N. Wang*, Y. Zhao*, B. Zhang*, Analysis of the medication rules of traditional Chinese medicines (TCMs) in treating liver cancer and potential TCMs exploration, Pharmacological Research - Modern Chinese Medicine, 2022, 3, 100086.

7. Y. Lu*, B. Zhang*, N. Wang, M. Li, N. Xi*, Investigation of Major Flavonoids from Artemisia argyi as a Potential COVID-19 Drug: Molecular Docking and DFT Calculations, Crystals, 2022, 12, 990.

8. Z.D. Dou, X.P. He, P. Xu, B. Zhang*, L.J. Ding*, Rapid separation and purification of two C25 steroids with bicyclic [4.4.1] A/B rings from the marine fungus Aspergillus sp. LS116 by high-speed counter-current chromatography in stepwise elution mode. Natural Product Research, 2022, 36, 3770-3774.

9. P. Zhang, Z. Wang, C. Mou, J. Zou, Y. Xie, Z. Liu, C. Benjamin Naman, Y. Mao, J. Wei, X. Huang, J. Dong, M. Yang, N. Wang, H. Jin, F. Liu, D. Lin, H. Liu, F. Zhou, S. He, B. Zhang*, W. Cui*, Design and synthesis of novel tacrine-dipicolylamine dimers that are multiple-target-directed ligands with potential to treat Alzheimer’s disease, Bioorganic Chemistry, 2021, 116, 105387.

10. Q.T. Zhang, Z.Y. Wang, X.Y. Chen, H.X. Qiu, Y.F. Gu, N. Wang*, T. Wang, Z. Wang, H.B. Ma, Y.F. Zhao*, B. Zhang*, 8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1, International Journal of Molecular Sciences, 2021, 22, 5516.

11. Q.T. Zhang, Z.D. Liu, Z. Wang, T. Wang, N. Wang, N. Wang*, B. Zhang*, Y.F. Zhao, Recent Advances in Small Peptides of Marine Origin in Cancer Therapy. Marine Drugs, 2021, 19, 115.

12. B. Zhang, J.M. Zou, Q.T. Zhang, Z. Wang, N. Wang*, S. He, Y.F. Zhao, C. B. Naman*, Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 2408.

13. T. Wang, Q.T. Zhang, N. Wang*, Z.Q. Liu, B. Zhang*, Y.F. Zhao, Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry, 2021, 28, 3107-3146.

14. B. Zhang, T. Zhang, T.Y. Zhang, N. Wang*, S. He, B. Wu, H.X. Jin*, A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb. International Journal of Molecular Sciences, 2020, 21, 5077.

15. B. Zhang, Q.T. Zhang, Z.D. Liu, N. Wang*, H.X. Jin, F. Liu, C.L. Zhang, S. He*, Synthesis and Anticancer Research of N‐(2‐aminophenyl)benzamide Acridine Derivatives as Dual Topoisomerase I and Isoform‐Selective HDAC Inhibitors. ChemistrySelect, 2020, 5, 8311-8318.

16. B. Zhang, Z.D. Dou, Z. Xiong, N. Wang*, S. He, X.J. Yan, H.X. Jin*, Design, synthesis and biological research of novel N-phenyl benzamide-4 methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents, Bioorganic & Medicinal Chemistry Letters, 2019, 23, 126714.

17. T. Li, N. Wang, T. Zhang, B. Zhang*, T.P. Sajeevan, V. Joseph, L. Armstrong, S. He, X.J. Yan and C.B. Naman*, A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors, Marine Drugs, 2019, 17, 493.

18. N. Wang, P.P. Qiu, W.Cui, X.J. Yan, B. Zhang* and S. He*, Recent advances in multi-target anti-Alzheimer disease compounds (2013 up to present), Current Medicinal Chemistry, 2019, 26, 5684-5710.

19. B. Zhang1, N. Wang1, C.L. Zhang, C.M. Gao*, W. Zhang, K. Chen, W.B. Wu, Y.Z. Chen, C.Y. Tan, Y.Y. Jiang*, Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment. European Journal of Medicinal Chemistry, 2017, 129, 337-348.

20. Z.S. Cui, X. Li, B. Li, B. Zhang*, C. M. Gao*, Y. Chen, C. Tan, H. Liu, W. Xie, T. Yang, Y.Y. Jiang, Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Bioorganic & Medicinal Chemistry, 2016, 24, 261-269.

21. B. Zhang, K. Chen, N. Wang, C. M. Gao*, Q. Sun, L. Li, Y. Chen, C. Tan, H. Liu, Y.Y. Jiang*, Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents. European Journal of Medicinal Chemistry, 2015, 93, 214-226.

22. B. Zhang, X. Li, B. Li, C. Gao, Y. Jiang, Acridine and its derivatives: a patent review (2009-2013), Expert Opinion on Therapeutic Patents, 2014, 24, 647-664.

近年主持/参与的项目

1. 宁波大学研究生课程建设经费（432203713），《药物合成与分析表征》，2023.05-2024.05，主持。

2. 靶向eEF2K抗肿瘤小分子抑制剂的设计、合成及活性评价，宁波市自然科学基金(2021J104)，2021.11-2023.10，主持。

3. 靶向DNMT/HDAC小分子抑制剂的设计、合成及抗癌研究，国家重点实验室开放基金（ZX2019001102），2020.01-2020.12，主持。

4. 伊维菌素氨基衍生物及其衍生化分子探针的合成，横向项目（HX2019000249），2019.07-2021.06，主持。

5. 基于拓扑异构酶（Topo II）与HDAC双靶点抑制剂的设计、合成及生物学研究，宁波市自然科学基金 (2018A610410)，2018.11-2020.10，主持。

6. 宁波大学科研项目（XYL18004），2018.01-2019.12，主持。

已获授权的发明专利

1. 一种1,2,3,4-四氢吖啶-9-胺类化合物及其制备方法和用途，CN112409335B。

2. 多取代苯基烷氨基吖啶酮-4-酰胺类化合物及其制备方法和用途，CN105693609B。

3. 一种氮杂芳环烷基氨基吖啶酮-4-酰胺类化合物及其制备方法与应用，CN104262327B。

4. 多取代嘧啶酮类化合物及其制备方法和应用，CN102617487B。

5. 便于移动的微生物培养装置，CN211814402U。

著作编写

学术兼职

浙江省药学会药物化学与抗生素专委会第二届青委会委员。